IL154111A0 - Synthesis of intermediates for the preparation of growth hormone secretagogues - Google Patents

Synthesis of intermediates for the preparation of growth hormone secretagogues

Info

Publication number
IL154111A0
IL154111A0 IL15411198A IL15411198A IL154111A0 IL 154111 A0 IL154111 A0 IL 154111A0 IL 15411198 A IL15411198 A IL 15411198A IL 15411198 A IL15411198 A IL 15411198A IL 154111 A0 IL154111 A0 IL 154111A0
Authority
IL
Israel
Prior art keywords
intermediates
synthesis
preparation
growth hormone
hormone secretagogues
Prior art date
Application number
IL15411198A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL154111A0 publication Critical patent/IL154111A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
IL15411198A 1997-06-25 1998-06-05 Synthesis of intermediates for the preparation of growth hormone secretagogues IL154111A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5079097P 1997-06-25 1997-06-25
PCT/IB1998/000876 WO1998058949A1 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues
IL13362698A IL133626A0 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues

Publications (1)

Publication Number Publication Date
IL154111A0 true IL154111A0 (en) 2003-07-31

Family

ID=21967444

Family Applications (7)

Application Number Title Priority Date Filing Date
IL15411198A IL154111A0 (en) 1997-06-25 1998-06-05 Synthesis of intermediates for the preparation of growth hormone secretagogues
IL15411598A IL154115A0 (en) 1997-06-25 1998-06-05 Process for the preparation of growth hormone secretagogues
IL15646598A IL156465A (en) 1997-06-25 1998-06-05 Scrotagogens of growth hormone for use in the treatment of sleep disorders
IL15411298A IL154112A0 (en) 1997-06-25 1998-06-05 Synthesis of intermediates for the preparation of growth hormone secretagogues
IL15411698A IL154116A0 (en) 1997-06-25 1998-06-05 Sythesis of intermediates for the preparation of growth hormone secretagogues
IL13362698A IL133626A0 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues
IL15411498A IL154114A0 (en) 1997-06-25 1998-06-05 Composition for use as a medicament for increasing levels of endogeneous growth hormone

Family Applications After (6)

Application Number Title Priority Date Filing Date
IL15411598A IL154115A0 (en) 1997-06-25 1998-06-05 Process for the preparation of growth hormone secretagogues
IL15646598A IL156465A (en) 1997-06-25 1998-06-05 Scrotagogens of growth hormone for use in the treatment of sleep disorders
IL15411298A IL154112A0 (en) 1997-06-25 1998-06-05 Synthesis of intermediates for the preparation of growth hormone secretagogues
IL15411698A IL154116A0 (en) 1997-06-25 1998-06-05 Sythesis of intermediates for the preparation of growth hormone secretagogues
IL13362698A IL133626A0 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues
IL15411498A IL154114A0 (en) 1997-06-25 1998-06-05 Composition for use as a medicament for increasing levels of endogeneous growth hormone

Country Status (40)

Country Link
US (3) US6448263B1 (cg-RX-API-DMAC7.html)
EP (1) EP1000085B1 (cg-RX-API-DMAC7.html)
JP (2) JP2000514099A (cg-RX-API-DMAC7.html)
KR (1) KR20010014224A (cg-RX-API-DMAC7.html)
CN (2) CN1530107A (cg-RX-API-DMAC7.html)
AP (1) AP1145A (cg-RX-API-DMAC7.html)
AR (1) AR012256A1 (cg-RX-API-DMAC7.html)
AT (1) ATE305477T1 (cg-RX-API-DMAC7.html)
AU (1) AU747510B2 (cg-RX-API-DMAC7.html)
BG (1) BG104008A (cg-RX-API-DMAC7.html)
BR (1) BR9810477A (cg-RX-API-DMAC7.html)
CA (1) CA2294464A1 (cg-RX-API-DMAC7.html)
CO (1) CO4950621A1 (cg-RX-API-DMAC7.html)
DE (1) DE69831745T2 (cg-RX-API-DMAC7.html)
DZ (1) DZ2539A1 (cg-RX-API-DMAC7.html)
EA (1) EA002089B1 (cg-RX-API-DMAC7.html)
EG (1) EG21712A (cg-RX-API-DMAC7.html)
ES (1) ES2248899T3 (cg-RX-API-DMAC7.html)
HN (1) HN1998000088A (cg-RX-API-DMAC7.html)
HR (1) HRP980361A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0001922A3 (cg-RX-API-DMAC7.html)
ID (1) ID24345A (cg-RX-API-DMAC7.html)
IL (7) IL154111A0 (cg-RX-API-DMAC7.html)
IN (1) IN189724B (cg-RX-API-DMAC7.html)
IS (1) IS5275A (cg-RX-API-DMAC7.html)
MA (1) MA24581A1 (cg-RX-API-DMAC7.html)
NO (1) NO996205D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ500655A (cg-RX-API-DMAC7.html)
OA (1) OA11242A (cg-RX-API-DMAC7.html)
PA (1) PA8452601A1 (cg-RX-API-DMAC7.html)
PE (1) PE105399A1 (cg-RX-API-DMAC7.html)
PL (1) PL337659A1 (cg-RX-API-DMAC7.html)
SK (1) SK175699A3 (cg-RX-API-DMAC7.html)
TN (1) TNSN98113A1 (cg-RX-API-DMAC7.html)
TR (1) TR199903257T2 (cg-RX-API-DMAC7.html)
TW (1) TW553943B (cg-RX-API-DMAC7.html)
UA (1) UA64751C2 (cg-RX-API-DMAC7.html)
WO (1) WO1998058949A1 (cg-RX-API-DMAC7.html)
YU (1) YU70199A (cg-RX-API-DMAC7.html)
ZA (1) ZA985546B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
US6541634B2 (en) * 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US7721948B1 (en) * 1999-05-25 2010-05-25 Silverbrook Research Pty Ltd Method and system for online payments
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
CA2496687A1 (en) * 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Ghrh analogues
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
BRPI0519728B1 (pt) * 2004-12-21 2016-12-13 Hercules Inc resinas catiônicas reativas e processo de fabricação de papel
US20070024388A1 (en) * 2005-07-27 2007-02-01 Hassan Tanbakuchi Slabline structure with rotationally offset ground
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
US9371297B2 (en) 2007-02-09 2016-06-21 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
RU2403902C1 (ru) * 2009-06-15 2010-11-20 Илья Николаевич Медведев Способ снижения биологического возраста при нарушении толерантности к глюкозе
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
KR102221002B1 (ko) * 2013-05-28 2021-02-26 라퀄리아 파마 인코포레이티드 다형체
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
TWI724995B (zh) * 2014-08-05 2021-04-21 日商拉夸里亞創藥股份有限公司 作為生長激素釋放肽受體激動劑之絲胺酸衍生物
CN106795158A (zh) * 2014-10-31 2017-05-31 拉夸里亚创药株式会社 作为生长激素释放肽受体激动剂的四氢吡唑并吡啶衍生物
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CN120265641A (zh) * 2023-04-21 2025-07-04 长春金赛药业有限责任公司 GHSR 1a激动剂、药物组合物及其制备方法和应用
CN119285632A (zh) * 2024-10-09 2025-01-10 威海中腾医药科技有限公司 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235550A (en) 1966-02-15 Anal g gesiaxoat t tail intravenous injection
US3202660A (en) 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US5242783A (en) 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
JPH08503213A (ja) 1992-11-06 1996-04-09 メルク エンド カンパニー インコーポレーテッド 成長ホルモンの放出を促進する置換ジペプチド同族体
CZ151495A3 (en) 1992-12-11 1995-12-13 Merck & Co Inc Spiropiperidine derivatives, process of their preparation and a pharmaceutical composition containing thereof
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
PL322706A1 (en) 1993-11-09 1998-02-16 Merck & Co Inc Piperidines, pyrolidines and hexahydro-1h-azepins enhancing growth hormone liberation
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
EP0766966A3 (en) 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
IL124702A0 (en) 1995-12-22 1998-12-06 Novo Nordisk As Compounds with growth hormone releasing properties
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
WO1998058947A1 (en) * 1997-06-25 1998-12-30 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)

Also Published As

Publication number Publication date
PL337659A1 (en) 2000-08-28
AU7445698A (en) 1999-01-04
US6448263B1 (en) 2002-09-10
AP9801267A0 (en) 1998-06-30
IL133626A0 (en) 2001-04-30
DE69831745T2 (de) 2006-08-31
AU747510B2 (en) 2002-05-16
IS5275A (is) 1999-11-26
NO996205L (no) 1999-12-15
US20030100561A1 (en) 2003-05-29
CN1530107A (zh) 2004-09-22
JP3742643B2 (ja) 2006-02-08
IL156465A0 (en) 2004-01-04
BG104008A (en) 2000-07-31
NZ500655A (en) 2002-02-01
US6867202B1 (en) 2005-03-15
US6630487B2 (en) 2003-10-07
IL154115A0 (en) 2003-07-31
JP2000514099A (ja) 2000-10-24
KR20010014224A (ko) 2001-02-26
HUP0001922A2 (hu) 2000-12-28
IL154112A0 (en) 2003-07-31
CO4950621A1 (es) 2000-09-01
EG21712A (en) 2002-02-27
WO1998058949A1 (en) 1998-12-30
IL154116A0 (en) 2003-07-31
EA199901075A1 (ru) 2000-08-28
JP2005097261A (ja) 2005-04-14
EP1000085A1 (en) 2000-05-17
ZA985546B (en) 2000-01-10
SK175699A3 (en) 2001-04-09
BR9810477A (pt) 2007-05-22
NO996205D0 (no) 1999-12-15
HUP0001922A3 (en) 2001-02-28
IL156465A (en) 2004-07-25
TNSN98113A1 (fr) 2005-03-15
UA64751C2 (uk) 2004-03-15
EA002089B1 (ru) 2001-12-24
ATE305477T1 (de) 2005-10-15
TW553943B (en) 2003-09-21
ES2248899T3 (es) 2006-03-16
AR012256A1 (es) 2000-09-27
CN1259140A (zh) 2000-07-05
HK1028051A1 (en) 2001-02-02
DE69831745D1 (de) 2006-02-09
DZ2539A1 (fr) 2003-02-08
IL154114A0 (en) 2003-07-31
HN1998000088A (es) 1999-01-08
AP1145A (en) 2003-02-14
MA24581A1 (fr) 1998-12-31
CA2294464A1 (en) 1998-12-30
ID24345A (id) 2000-07-13
CN1152049C (zh) 2004-06-02
HRP980361A2 (en) 1999-02-28
TR199903257T2 (xx) 2000-12-21
OA11242A (en) 2003-07-23
YU70199A (sh) 2003-01-31
IN189724B (cg-RX-API-DMAC7.html) 2003-04-19
PE105399A1 (es) 1999-11-04
PA8452601A1 (es) 2000-05-24
EP1000085B1 (en) 2005-09-28

Similar Documents

Publication Publication Date Title
IL154112A0 (en) Synthesis of intermediates for the preparation of growth hormone secretagogues
AP9901555A0 (en) Dipeptide compounds which are growth hormone secretagogues
IL134596A0 (en) Growth hormone secretagogues
IL133043A0 (en) Process and intermediates for growth hormone secretagogues
EP1021407A4 (en) SYNTHESIS OF CLASTO-LACTACYSTINE BETA-LACTONE AND ITS ANALOGS
IL121730A0 (en) Process for the preparation of 2'-fluoro-5-methyl-beta-L-arabino-furanosyluridine
IL126272A0 (en) Synthesis of indolylmaleimides
IL131660A0 (en) Process for preparation of pesticidal intermediates
IL133140A0 (en) Novel process for the preparation of 4-aryl-piperidines
IL143783A (en) Intermediates for the preparation of eprosartan
GB9110610D0 (en) Preparation of intermediates for the synthesis of benzothiazepines
IL128376A0 (en) Synthesis of bisindolylmalimides
GB9823422D0 (en) Naptho-fused lactams promate release of growth hormone
EP1126854A4 (en) BENZOAZEPINES AND THEIR ANALOGS AS MEANS THAT PROMOTE THE SECRETION OF THE GROWTH HORMONE
EP0946411A4 (en) METHOD FOR PRODUCING NITRIDE CRYSTALS OF THE 3 MAIN GROUP
HU228274B1 (en) Intermediates for the preparation of 2-imidazoline-5-ones
IL125637A0 (en) Synthesis of carboxyalkylthiosuccinic acids
PL337612A1 (en) Crystalline form of roxyfiban
SI1004583T1 (en) Process and hydantoin intermediates for the synthesis of growth hormone secretagogues
HUP0003788A3 (en) Azacycloalkylalkanoyl pseudotetrapeptides intermediates and processes for preparation thereof
IL140786A0 (en) Process for the preparation of 4,6-disubstituted 2-isocyanatopyrimidines and their use as intermediates for active compound syntheses
ZA982453B (en) Synthesis of intermediates useful in preparing tricyclic compounds
IL124387A0 (en) Preparation of 5-Methyleneoxazolines
GB9720087D0 (en) Preparation of cyclopropylethyne and intermediates for preparation of cyclopropylethyne
IL120560A0 (en) Process for the preparation of pyrimidinone compounds and intermediates produced thereby